BACKGROUND & AIMS: The Baveno VI and the expanded Baveno VI criteria were proposed to help identify patients who could safely avoid screening endoscopies for clinically significant varices among patients with compensated advanced chronic liver disease. However, these criteria require cross-validation, especially in Asian populations where the aetiologies of liver disease are different. METHODS: A total of 1035 patients, including 282 patients with compensated advanced chronic liver disease of different aetiology, were analysed. The compensated advanced chronic liver disease was defined by liver stiffness measurement ≥10 kPa, Child-Pugh class A and absence of prior liver decompensation. High-risk varix was defined as a grade ≥2 oesophageal varix, any varix with a red colour sign or gastric varices. RESULTS: High-risk varixs were present in 19.5% (55/282 patients) with compensated advanced chronic liver disease. Among compensated advanced chronic liver disease patients, the expanded criteria could spare more endoscopies (51.7%) than the original criteria (27.6%). However, the expanded criteria missed a greater number of high-risk varixs (6.8%) than the original criteria (3.8%). When stratified according to liver disease aetiology, the negative predictive values for the original Baveno VI criteria were 0.92, 1.00, 1.00 and 1.00, and the negative predictive values for the expanded criteria were 0.92, 0.96, 0.92 and 0.93 for hepatitis B, hepatitis C, alcohol and non-alcoholic fatty liver disease, respectively. High-risk varixs were rarely detected in patients without compensated advanced chronic liver disease (1.1%, 8/753 patients). CONCLUSIONS: In this Asian cohort study, the Baveno VI criteria were able to identify who could safely avoid screening endoscopy. The expanded Baveno VI criteria could spare more endoscopies but also could increase the odds of missing a high-risk varix.
BACKGROUND & AIMS: The Baveno VI and the expanded Baveno VI criteria were proposed to help identify patients who could safely avoid screening endoscopies for clinically significant varices among patients with compensated advanced chronic liver disease. However, these criteria require cross-validation, especially in Asian populations where the aetiologies of liver disease are different. METHODS: A total of 1035 patients, including 282 patients with compensated advanced chronic liver disease of different aetiology, were analysed. The compensated advanced chronic liver disease was defined by liver stiffness measurement ≥10 kPa, Child-Pugh class A and absence of prior liver decompensation. High-risk varix was defined as a grade ≥2 oesophageal varix, any varix with a red colour sign or gastric varices. RESULTS: High-risk varixs were present in 19.5% (55/282 patients) with compensated advanced chronic liver disease. Among compensated advanced chronic liver diseasepatients, the expanded criteria could spare more endoscopies (51.7%) than the original criteria (27.6%). However, the expanded criteria missed a greater number of high-risk varixs (6.8%) than the original criteria (3.8%). When stratified according to liver disease aetiology, the negative predictive values for the original Baveno VI criteria were 0.92, 1.00, 1.00 and 1.00, and the negative predictive values for the expanded criteria were 0.92, 0.96, 0.92 and 0.93 for hepatitis B, hepatitis C, alcohol and non-alcoholic fatty liver disease, respectively. High-risk varixs were rarely detected in patients without compensated advanced chronic liver disease (1.1%, 8/753 patients). CONCLUSIONS: In this Asian cohort study, the Baveno VI criteria were able to identify who could safely avoid screening endoscopy. The expanded Baveno VI criteria could spare more endoscopies but also could increase the odds of missing a high-risk varix.
Authors: Michael Colwill; Luke Lake; Ahmed El-Sayed; Jonathan King; Rawen Kader; Eathar Shakweh; Andra Caracostea; Louise China; James Maurice Journal: Future Healthc J Date: 2022-03
Authors: Bubu A Banini; Samarth Patel; Jonathan W Yu; Le Kang; Christopher Bailey; Brian J Strife; Mohammad S Siddiqui; Vaishali Patel; Scott C Matherly; Hannah Lee; Shawn Lewis; Reena Cherian; Richard T Stravitz; Velimir Luketic; Arun J Sanyal; Richard K Sterling Journal: J Clin Gastroenterol Date: 2022-01-10 Impact factor: 3.174
Authors: Theresa Hydes; Michael Moore; Beth Stuart; Miranda Kim; Fangzhong Su; Colin Newell; David Cable; Alan Hales; Nick Sheron Journal: BMJ Open Date: 2021-02-11 Impact factor: 2.692
Authors: Morven E Cunningham; Gilda Parastandeh-Chehr; Orlando Cerocchi; David K Wong; Keyur Patel Journal: Can J Gastroenterol Hepatol Date: 2019-02-07
Authors: Zsolt Szakács; Bálint Erőss; Alexandra Soós; Péter Mátrai; Imre Szabó; Erika Pétervári; Judit Bajor; Nelli Farkas; Péter Hegyi; Anita Illés; Margit Solymár; Márta Balaskó; Patrícia Sarlós; Ákos Szűcs; József Czimmer; Áron Vincze; Gabriella Pár Journal: Front Physiol Date: 2019-08-13 Impact factor: 4.566
Authors: Adonis A Protopapas; Theodora Mylopoulou; Vasileios P Papadopoulos; Kiriaki Vogiatzi; Ioannis Goulis; Konstantinos Mimidis Journal: Ann Gastroenterol Date: 2019-10-23